Evidence-based development of liver allocation: A review

Transplant International

Volumn 24, Issue 10, 2011, Pages 965-972

  Merion, Robert M ^a   Sharma, Pratima ^b   Mathur, Amit K ^b   Schaubel, Douglas E ^c  

^a ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

donation; donor management; donor registries; education; liver; liver clinical; organ allocation; organ preservation and procurement; pediatric transplantation

Indexed keywords

CHILD TURCOTTE PUGH SCORE; END STAGE LIVER DISEASE; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HOSPITAL ADMISSION; HUMAN; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ORGAN DONOR; PRIORITY JOURNAL; REVIEW;

CHILD; END STAGE LIVER DISEASE; EVIDENCE-BASED MEDICINE; HUMANS; LIVER; LIVER TRANSPLANTATION; ORGAN PRESERVATION; REGISTRIES; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TREATMENT OUTCOME; WAITING LISTS;

EID: 80955178820     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01274.x     Document Type: Review

References (29)

1. Freeman Jr RB,. Liver allocation: The U.S. Model. In:, Busuttil RW, Klintmalm GK, eds. Transplantation of the Liver, 2nd edn. Philadelphia, PA: Elsevier Saunders, 2005: pp. 63-77.
2. Freeman Jr RB, Wiesner RH, Roberts JP, McDiarmid S, Dykstra DM, Merion RM,. Improving liver allocation: MELD and PELD. Am J Transplant 2004; 4 (Suppl. 9): 114.
3. Institute of Medicine. Organ Procurement and Transplantation: Assessing Current Policies and the Potential Impact of the DHHS Final Rule. Washington, D.C.: National Academy Press, 1999.
4. Gallegos-Orozco JF, Vargas HE,. Liver transplantation: from Child to MELD. Med Clin North Am 2009; 93: 931, ix.
5. Child CG, Turcotte JG,. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1.
6. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91.
7. Freeman Jr RB, Edwards EB,. Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy. Liver Transpl 2000; 6: 543.
8. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC,. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864.
9. Harrell Jr FE, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361.
10. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464.
11. Freeman Jr RB, Gish RG, Harper A, et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006; 12: S128.
12. Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567.
13. UNOS. 3.6 Organ distribution: allocation of livers, 2002. Available at: (accessed January 12, 2007).
14. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA,. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307.
15. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R,. Results of the first year of the new liver allocation plan. Liver Transpl 2004; 10: 7.
16. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
17. Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992; 16: 132.
18. Sharma P, Balan V, Hernandez JL, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004; 10: 36.
19. Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003; 9: 684.
20. Wiesner RH, Freeman RB, Mulligan DC,. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004; 127: S261.
21. Pomfret EA, Fryer JP, Sima CS, Lake JR, Merion RM,. Liver and intestine transplantation in the United States, 1996-2005. Am J Transplant 2007; 7: 1376.
22. Thompson D, Waisanen L, Wolfe RA, Merion RM, McCullough KP, Rodgers A,. Simulating the allocation of organs for transplantation. Health Care Manag Sci 2004; 7: 331.
23. Sharma P, Schaubel DE, Sima CS, Merion RM, Lok AS,. Re-weighting the model for end-stage liver disease score components. Gastroenterology 2008; 135: 1575.
24. Gonwa TA, McBride MA, Anderson K, Mai ML, Wadei H, Ahsan N,. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006; 6: 2651.
25. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
26. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM,. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419.
27. Lucey MR, Schaubel DE, Guidinger MK, Tome S, Merion RM,. Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. Hepatology 2009; 50: 400.
28. Schaubel DE, Guidinger MK, Biggins SW, et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009; 9: 970.
29. Englesbe MJ, Schaubel DE, Cai S, Guidinger MK, Merion RM,. Portal vein thrombosis and liver transplant survival benefit. Liver Transpl 2010; 16: 999.